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Purpose: Preventing cerebral embolism from debris produced during carotid artery stenting (CAS) is important.
This study compared the treatment outcomes of CAS using two types of filter-based embolic protection devices
currently in use in Japan.
Materials and methods: We assessed 121 consecutive cases of CAS performed with FilterWire EZ™ between July
2010 and November 2012 and 37 consecutive cases of CAS performed with the Spider FX™ between November 2012
and June 2013. A Carotid Wallstent™ was used in all cases. The incidence of positive lesions on diffusion-weighted
magnetic resonance imaging (DWI) and stroke were compared between the groups.
Results: Postoperative DWI-positive lesions were observed in 38 (31.4%) and 14 (37.8%) patients in the FilterWire and
Spider groups, respectively. In the FilterWire group, complications were transient ischemic attacks in 3 (2.5%) patients,
cerebral infarction in 2 (1.7%) patients (1 patient each with minor and major stroke), and cerebral hemorrhage due
to hyperperfusion syndrome in 1 (0.8%) patient. In the Spider group, except for cerebral infarction (minor stroke) in
1 (2.7%) patient, no complications were observed. No significant differences were observed in the incidence of
complications between the groups.
Conclusion: FilterWire EZ and Spider FX are comparable in terms of treatment outcome.
Keywords: Carotid artery stenting; Cerebral infarction; Diffusion-weighted magnetic resonance imaging; Distal protection
filter deviceBackground
Carotid artery stenting (CAS), as a substitute for carotid
endarterectomy (CEA), is rapidly becoming a popular
treatment for carotid artery stenosis and has demon-
strated a treatment outcome comparable to that of CEA
(SPACE Collaborative Group et al. 2006). CAS is also
more effective than CEA in patients at high risk of CEA
complications (Yadav et al. 2004). Moreover, since its ef-
ficacy in medium-risk cases was recently reported (Brott
et al. 2010), CAS is becoming a widely used alternative
therapy to CEA. However, CAS is associated with the
risk of intraoperative embolism. Preventing peripheral
embolism is therefore important for improving the out-
comes of this procedure.* Correspondence: haikawa@cis.fukuoka-u.ac.jp
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Zokumyoin, Chikushino, Fukuoka 818-8502, Japan
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in any medium, provided the original work is pVarious methods have been proposed for embolism
prevention and can be roughly divided into proximal
protection, in which the proximal part of the lesion is
blocked with a balloon, and distal protection, in which
the distal part of the lesion is blocked with a balloon or
fitted with a filter. Distal protection techniques are tech-
nically more convenient than proximal techniques, and a
number of randomized trials have demonstrated the use-
fulness of embolic protection devices (EPDs) in prevent-
ing peripheral embolism.
In this article, we compare the outcomes of two types
of EPDs, in particular, distal protection filter devices:
FilterWire EZ™ (Boston Scientific, Natick, MA; hereafter
referred to as FilterWire) and Spider FX™ (Covidien,
Mansfield, MA; hereafter referred to as Spider).pen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Informed consent was obtained from all patients after
the nature of the procedures had been fully explained.
Approval was obtained from the Fukuoka University
Chikushi Hospital institutional review board. The
Declaration of Helsinki was followed.
This study involved 158 consecutive cases of CAS per-
formed at our hospital or affiliated institutions using ei-
ther the FilterWire or Spider device. Cases performed by
proximal protection or unprotected procedures were ex-
cluded. A total of 121 consecutive cases of CAS were
performed with the FilterWire between July 2010 and
November 2012 and the remaining 37 consecutive cases
were performed with the Spider between November
2012 and June 2013. The Carotid Wallstent™ Monorail
stent (Boston Scientific, Natick, MA) was used in all
cases. The incidence of intraoperative flow impairment,
ischemic cerebrovascular events, and hyperperfusion
syndrome during the first 7 postoperative days and the
incidence of positive lesions on diffusion-weighted mag-
netic resonance (MR) imaging (DWI) were compared
between the two groups. Patients were considered eli-
gible for CAS if they had a symptomatic stenosis ≥50%
of the carotid artery or an asymptomatic stenosis ≥80%
of the carotid artery, according to the criteria proposed
in the North American Symptomatic Carotid Endarter-
ectomy Trial (NASCET) (North American Symptomatic
Carotid Endarterectomy Trial Collaborators 1991).
Before the procedure, all patients underwent MR plaque
imaging with a Philips Ingenia 1.5 T scanner (Philips Health-
care, Heide, Netherlands). On black blood T1-weighted,
black blood T2-weighted, and time-of-flight images, the sig-
nal intensity of the plaque within the carotid artery was
compared with that of the ipsilateral sternocleidomastoid
muscle. Plaques with intraplaque hemorrhage and a lipid-
rich necrotic core were defined as vulnerable and those
with fibrous tissue and calcification were defined as
stable (Sakamoto et al. 2010).
All patients were treated with two of three oral anti-
platelet drugs (aspirin 100 mg daily, clopidogrel 75 mg
daily, or cilostazol 200 mg daily) for at least 5 days be-
fore the procedure. Under general anesthesia, an 8-Fr
sheath was inserted into the femoral artery through
which heparin (80 IU/kg) was infused intravenously to
achieve an activated clotting time of ≥250 s. An 8-Fr
guiding catheter was advanced into the common carotid
artery on the affected side, and the FilterWire or Spider
device was advanced through the narrowing portion into
the distal part of the internal carotid artery. Angiography
was then performed to confirm that antegrade blood
flow was observed after the filter was unfolded. A
stent was placed after balloon pre-dilatation, and post-
dilatation was performed if residual stenosis ≥20% was
observed, in accordance with the NASCET criteria.Angiography was also performed to identify any flow im-
pairment. Flow impairment consisted of “stop flow”, de-
fined as disrupted blood flow, and “low flow”, defined as
delayed visualization of the internal carotid artery com-
pared with the external carotid artery. If flow impair-
ment was identified, 60 ml blood was aspirated from the
vicinity of the protection device, followed by device re-
moval. In the event of bradycardia or hypotension dur-
ing the procedure, atropine sulfate or a vasopressor was
used in the appropriate manner. After the operation,
heparin neutralization was not performed and the punc-
ture site was treated with a hemostatic device (Angio-Seal,
St. Jude Medical. Inc., St. Paul, MN). The patient was then
transferred to the intensive care unit or special care unit
and, immediately after recovery from anesthesia, was
monitored for any neurological symptoms.
All patients underwent head MR imaging upon the
onset of new neurological symptoms or, for asymptom-
atic patients, at 1–3 days after operation to identify any
new ischemic lesions in the brain. The Philips Ingenia
1.5 T MR imaging apparatus was used to obtain fluid-
attenuated inversion recovery (FLAIR) and DWI images.
DWI images were obtained with the following parame-
ters: b value 1,000 s/mm2, repetition time/echo time/
excitation 3803 ms/92 ms/1, 128 × 128 matrix, field of
view 230 × 230 mm, 5 mm slice thickness, and 0.5 mm
interslice gap, with a total acquisition time of 45 s. The
parameters for FLAIR images were repetition time/echo
time/excitation 11,000 ms/110 ms/1, 272 × 272 matrix,
field of view 230 × 230 mm, 5 mm slice thickness, and
0.5 mm interslice gap, with a total acquisition time of
2 min 45 s. New cerebral ischemic lesions (DWI-positive
lesions) were identified on FLAIR, DWI, or apparent diffu-
sion coefficient maps, and the number of non-contiguous
lesions was counted. Image analysis was performed by two
neurosurgeons who did not perform the CAS procedures.
Ischemic neurological events were classified into
transient ischemic attack (TIA; defined as neurological
deficit symptoms that improved within 24 h), minor
stroke (defined as prolonged neurological deficit symp-
toms persisting >24 h and a National Institute of
Health Stroke Scale [NIHSS] score of ≤4), and major
stroke (defined as prolonged neurological deficit symp-
toms persisting for >24 h and an NIHSS score of ≥5).
Hyperperfusion syndrome was defined as the presence
of postoperative intracranial hemorrhage with an in-
crease in cerebral blood flow of >100% compared with
the preoperative value, as determined by a cerebral
blood flow test.
For statistical comparison of clinical characteristics be-
tween the two groups, the independent t-test was used
for age and the degree of stenosis, while Pearson’s Chi-
squared test was used for sex-related differences and the
frequency of pre- and postoperative risk factors. The
Table 2 Flow impairment and postoperative stroke







Flow impairment 14 (11.6%) 1 (2.7%) 0.19*
Postoperative stroke event
TIA or amaurosis fugax 3 (2.5%) 0 (0%) 1*
Minor stroke 1 (0.8%) 1 (2.7%) 0.41*
Major stroke 1 (0.8%) 0 (0%) 0.49*
Total ischemic neurological events 5 (4.1%) 1 (2.7%) 1*
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events, and hyperperfusion syndrome was analyzed using
Fisher’s exact test and that of postoperative DWI-positive
lesions was analyzed using Pearson’s Chi-squared test.
Significance was set at p ≤ 0.05.
Results
The clinical characteristics of patients in both groups
are summarized in Table 1. No significant differences
were found between the groups with regard to patient
demographics, and stent placement was successful in all
patients in both groups. Direct puncture of the common
carotid artery was performed in 2 patients in the Filter-
Wire group and in no patients in the Spider group.
Flow impairment was observed in 14 (11.6%) patients in
the FilterWire group and in 1 (2.7%) patient in the Spider
group. The incidence of flow impairment was lower, but
not significantly, in the Spider group (p = 0.19).
Ischemic neurological events were observed in 6 (3.8%)
patients in the entire study population. Of the 5 (4.1%)
cases that occurred in the FilterWire group, 3 (2.5%) were
TIA, 1 (0.8%) was minor stroke, and 1 (0.8%) was major
stroke. The 1 (2.7%) case in the Spider group was minor
stroke. Hyperperfusion syndrome was observed in 3
(2.5%) patients in the FilterWire group, of which 2 had
only headache and the remaining 1 had extensive intra-
cranial hemorrhage and required craniotomy. Hyper-
perfusion syndrome was also observed in 2 (5.4%)
patients in the Spider group. Both patients had onlyTable 1 Baseline characteristics of patients who
underwent carotid artery stenting with different







Mean age (years) 72.6 ± 9.0 71.1 ± 8.6 0.39*
Male 104 (84%) 29 (78%) 0.26**
Cardiovascular risk factor
Diabetes mellitus 38 (31%) 13 (37%) 0.67**
Hypertension 96 (79%) 29 (78%) 0.89**
Dyslipidemia 58 (48%) 20 (54%) 0.51**
Atrial fibrillation 15 (11%) 4 (11%) 0.79**
History of cardiovascular disease 22 (18%) 6 (16%) 0.78**
Presenting symptom
Cerebral infarction 53 (43%) 18 (48%) 0.60**
TIA3 or amaurosis fugax 11 (9.1%) 4 (11%) 0.75**
Asymptomatic 57 (47%) 15 (41%) 0.48**
Degree of carotid artery stenosis 77.5 ± 13.1 75.2 ± 14.6 0.39*
1FilterWire EZ™.
2Spider FX™.
3TIA, transient ischemic attacks.
*Independent t-test; **Pearson’s Chi-squared test.headache and no neurological deficit symptoms were
observed. Furthermore, no significant intergroup differ-
ences were observed in the incidence of ischemic
neurological events (p = 1.00) or hyperperfusion syn-
drome (p = 0.33) (Table 2).
Postoperative DWI-positive lesions were observed in
38 (31.4%) patients in the FilterWire group and in 14
(37.8%) patients in the Spider group, with no significant
differences (p = 0.47). The number of patients who had
1, 2, and ≥3 DWI-positive lesions was 16 (13.2%), 9
(7.4%), and 13 (10.7%) in the FilterWire group and 5
(13.5%), 3 (8.1%), and 6 (12.3%) in the Spider group, re-
spectively, with no significant differences between the
groups (p = 0.96, p = 0.89, and p = 0.37, respectively)
(Table 3). Of the 14 patients with flow impairment in
the FilterWire group, 2 (14.2%) had ischemic neuro-
logical events and 8 (57.1%) had postoperative DWI-
positive lesions. The incidence of these complications
was higher than that in the 107 patients without flow
impairment (ischemic neurological events in 3 (2.8%)
and postoperative DWI-positive lesions in 30 (28.0%)
patients), with a significantly higher incidence of postop-
erative DWI-positive lesions in patients with flow im-
pairment (p = 0.10 and p = 0.03, respectively) (Table 4).






New white lesions on DWI3 38 (31.4%) 14 (37.8%) 0.47*
No. of new white lesions
1 16 (13.2%) 5 (13.5%) 0.96*
2 9 (7.4%) 3 (8.1%) 0.89*
≥3 13 (10.7%) 6 (12.3%) 0.37*
1FilterWire EZ™.
2Spider FX™.
3DWI, diffusion-weighted magnetic resonance imaging.
*Pearson’s Chi-squared test.








2 (14.2%) 3 (2.8%) 0.10*
New white lesions on
DWI1
8 (57.1%) 30 (28.0%) 0.03**
1DWI, diffusion-weighted magnetic resonance imaging.
*Fisher’s exact test; **Pearson’s Chi-squared test.
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impairment in the Spider group.
Of the 66 patients with unstable plaque in the Filter-
Wire group, 8 (12.1%) had flow impairment, 3 (4.5%) had
ischemic neurological events, and 27 (40.9%) had postop-
erative DWI-positive lesions. In comparison, of the 55
patients without unstable plaque in the FilterWire group,
6 (10.9%) had flow impairment, 2 (3.6%) had ischemic
neurological events, and 11 (20.0%) had postoperative
DWI-positive lesions, respectively, with a significantly
higher incidence of postoperative DWI-positive lesions
in patients with unstable plaque (p = 1.00, p = 1.00, and
p = 0.02, respectively). Of the 23 patients with unstable
plaque in the Spider group, 1 (4.3%) had flow impair-
ment, 1 (4.3%) had ischemic neurological events, and
10 (43.5%) had postoperative DWI-positive lesions. Of
the 14 patients without unstable plaque in the Spider
group, no patients had flow impairment or ischemic
neurological events and 4 (28.6%) had postoperative
DWI-positive lesions. No significant intergroup differ-
ences were observed in the incidence of ischemic
neurological events (p = 1.00) or postoperative DWI-
positive lesions (p = 0.36) (Table 5).Table 5 Outcome for patients with vulnerable or stable







Flow impairment 8 (12.1%) 6 (10.9%) 1*
Ischemic neurological
events
3 (4.5%) 2 (3.6%) 1*
New white lesions
on DWI






Flow impairment 1 (4.3%) 0 (0%) 1*
Ischemic neurological
events
1 (4.3%) 0 (0%) 1*
New white lesions
on DWI3
10 (43.5%) 4 (28.6%) 0.36**
1FilterWire EZ™.
2Spider FX™.
3DWI, diffusion-weighted magnetic resonance imaging.
*Fisher’s exact test; **Pearson’s Chi-squared test.Discussion
The use of EPDs has been shown to be effective in CAS
procedures (Kastrup et al. 2003, 2006) and these devices
are therefore routinely used in CAS. EPDs are roughly di-
vided into distal protection balloon (DPB) devices, which
block blood flow in a peripheral artery with a balloon to
prevent peripheral embolism caused by debris, and distal
protection filter (DPF) devices, which capture debris with
a filter placed in a peripheral artery. Kim et al. (2007)
compared the outcome of CAS using the PercuSurge
GuardWire™ DPB device (Medtronic, Minneapolis, MN)
in 33 patients with that of CAS using the FilterWireEX/
EZ DPF device with an Emboshield filter (Abbott Vascular,
Santa Clara, CA) in 38 patients and reported a similar in-
cidence of new ischemic lesions on DWI with both de-
vices. Zahn et al. (2005) also compared the outcomes of
CAS with DPB and DPF devices and found no significant
differences in the incidence of TIA, minor stroke, or
major stroke. Nevertheless, the fact that a decreased in-
cidence of ischemic lesions has been reported with the
FilterWire (Iko et al. 2013) suggests the superiority of
DPF devices as EPDs.
In addition to the FilterWire and Spider, currently
available DPF devices include the Angioguard™ XP
(Cordis Corp, Bridgewater, NJ), RX Accunet™ (Abbott
Vascular), Emboshield™ NAV6, and FiberNet™ (Lumen
Biomedical, Inc., Plymouth, MN). Loghmanpour et al.
(2013) compared the outcomes of these six DPF devices
and reported that the overall incidence of TIA and
stroke was 2.6% and 5.2%, respectively, and that al-
though the RX Accunet accounted for about 60% of all
devices used, there were no significant differences in
clinical outcome between the six devices. However, the
incidence of combined adverse events they reported
was 5.4% with the RX Accunet, 12.3% with the Filter-
Wire, and a relatively higher 17.8% with the Spider. On
the other hand, Iyer et al. (2007) reported the incidence
of combined adverse events with the RX Accunet, Fil-
terWire, and Spider to be as low as 5.9%, 2.2%, and
2.1%, respectively, which is comparable to that in the
present study. Different DPF devices have different
properties in terms of capture efficiency, porosity, vas-
cular resistance, wall apposition, pore density, and con-
centricity (Müller-Hülsbeck et al. 2002; Siewiorek et al.
2009; Loghmanpour et al. 2013). In particular, the
Spider has been shown to have lower capture efficiency
than other devices (Siewiorek et al. 2009). Meanwhile,
Loghmanpour et al. also reported that clinical outcome
is affected by the device’s porosity, wall apposition, and
pore density but not by capture efficacy (Loghmanpour
et al. 2013). This may explain why no significant differ-
ences have been found in treatment outcomes between
the FilterWire and Spider. The Spider has a larger pore
size than the FilterWire (110 μm vs. 70–200 μm) and,
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ture small particles. In the present study, CAS with the
Spider was associated with a higher but non-significant
incidence of postoperative DWI-positive lesions than
CAS with the FilterWire, which may be attributed to
the different filter properties. Since the clinical outcome in
the Spider group was similar to that reported by Iyer et al.
(2007), it is likely that the small DWI-positive lesions
caused by small debris not captured by the Spider did not
progress to cerebral infarction with the potential to cause
permanent neurological deficit symptoms.
The incidence of flow impairment in CAS with DPF
devices is 6–30%, whereas that with the FilterWire or
Spider is as low as 6–8% (Kwon et al. 2006; Roffi et al.
2008). In the present study, flow impairment was ob-
served in 14 (11.6%) patients in the FilterWire group
and in 1 (2.7%) patient in the Spider group, which is
similar to the results of previous studies. Furthermore,
normal blood flow in this study was re-established with
no signs of subsequent vasospasm in any cases of flow
impairment, indicating that the flow impairment was
caused by the filter clogging and not by vasospasm. Al-
though no significant differences were observed in the in-
cidence of flow impairment between the groups, those
patients with flow impairment in the FilterWire group
were more likely to have ischemic neurological events and
postoperative DWI-positive lesions, with a significantly
higher incidence of postoperative DWI-positive lesions in
patients with flow impairment than in those without. Cas-
serly et al. (2005) reported a significantly higher incidence
of stroke within 30 days of the operation in patients with
flow impairment (9.3%), compared with that in patients
with normal flow (1.7%), which is similar to the present
results. Flow impairment occurs with clogging of the filter
by debris produced during the CAS procedure and sub-
sequent blockage of peripheral blood flow by the
debris-filled filter. Thus, filters with higher capture effi-
ciency appear to be more likely to cause flow impair-
ment. The FilterWire has a smaller pore size and
higher capture efficiency than the Spider (Siewiorek
et al. 2009). Flow impairment causes debris to flow to-
wards the distal part of the internal carotid artery,
which may explain the increased incidence of ischemic
neurological events and postoperative DWI-positive le-
sions in patients with flow impairment. The incidence of
flow impairment with the Spider in the present study was
low (2.7%), which is also likely to be related to the filter’s
pore size and capture efficiency. These results might be
explained by the fact that the device is poor at capturing
small debris and thus is more likely to cause postoperative
DWI-positive lesions and less likely to cause flow impair-
ment and ischemic neurological events.
Unstable plaque contains apoptotic smooth muscle cells
and infiltrating inflammatory cells, such as macrophagesand lymphocytes, and is covered by a thinned and weak-
ened fibrous capsule (Virmani et al. 2006). CAS for in-
ternal carotid artery stenosis with unstable plaque can
cause plaque rupture and thrombus formation and
thereby increase the risk of cerebral infarction. van Lam-
meren et al. (2011) have suggested that the increased
aging of the population will lead to more CAS procedures
being performed in patients with unstable plaque, thereby
increasing the incidence of postoperative cerebral infarc-
tion. In the present study, the incidence of ischemic
neurological events and postoperative DWI-positive le-
sions was higher in patients with unstable plaque in both
groups, with significant differences in the FilterWire group.
Sakamoto et al. (2010) compared the incidence of flow im-
pairment and DWI-positive lesions after CAS in patients
with and without unstable plaque and found a significant
difference in the incidence of flow impairment but not in
that of DWI-positive lesions. Although the results of their
study cannot simply be compared with ours because they
used a different type of DPF device (Angioguard XP), it is
likely that unstable plaque is closely associated with the de-
velopment of flow impairment and postoperative DWI-
positive lesions. It therefore seems reasonable to consider
the use of proximal protection or carotid endarterectomy
in patients with unstable plaque and who are thus at high
risk of CAS complications.
The Carotid Wallstent Monorail stent (diameter, 10 mm;
length, 24 mm) was used in all cases in this study.
Although stenting was successful in all cases, the use of
an open-cell stent is preferable in patients with high le-
sion tortuosity in the carotid artery (Myouchin et al.
2013). In addition, the use of different type and size stents
is recommended depending on the length and shape
of the lesion in individual patients (Bates et al. 2007).
However, in accordance with our CAS policy, our hospital
and affiliated institutions use the same technique and de-
vice as often as possible to enable us to compare the out-
comes of CAS. Although we have used open-cell stents
in some patients, placement of the Carotid Wallstent
Monorail stent has, in our experience, been successful,
even in patients with high lesion tortuosity in the ca-
rotid artery and slight displacement of the flow path
when applying pressure from the surface of the cervix and
repositioning the guiding catheter in the peripheral direc-
tion. In addition, we also select the Carotid Wallstent
Monorail stent for its ability to prevent plaque protrusion.
We initially used the FilterWire as a distal protection
filter device for CAS but experienced difficulty in advan-
cing it through severely calcified or curved lesions. Since
the Spider could be advanced more easily through le-
sions and showed a comparable clinical outcome, this
prompted us to use the Spider in CAS. However, in
addition to DPF devices such as the two we used, several
other options are available as EPDs for CAS, including
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proximal protection method. We hope that the findings
of the present study will provide useful information for
determining the treatment strategy for carotid artery
stenosis.
This study has some limitations. It was not a random-
ized study: the first series of patients were treated with
the FilterWire and the subsequent series with the Spider
following favorable initial outcomes obtained with the
latter device. Although the possibility that improved
skills in the CAS procedure contributed to the improved
outcome was not taken into account, given that both the
FilterWire and Spider devices are filter-type EPDs, the
impact of greater technical proficiency that occurs with
a learning curve is considered small.
Conclusions
The FilterWire was associated with a higher incidence of
flow impairment and postoperative DWI-positive lesions
than the Spider in patients with unstable plaque. How-
ever, as no significant difference in the incidence of is-
chemic neurological events was apparent between the
FilterWire and Spider groups, the devices are considered
to be comparable in terms of treatment outcome.
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